Altamira rises on plans for RNA business, nasal spray

Altamira Therapeutics

30/08/2022 15:29

** Shares of biotech co Altamira Therapeutics  CYTO.O  rise
as much as 7.2% to 42 cents 
    ** CYTO says it is on track with plan to focus on its RNA
business  urn:newsml:reuters.com:*:nGNX4Rs5xl
    ** Says it is advancing talks to spin-off its legacy
business, including its Bentrio and AM-125 nasal spray programs
    ** Plans to file for authorization of its vertigo treatment
AM-123 in Q4 2022
    ** CYTO says advanced partnering discussions with a number
of parties for its U.S. FDA-approved anti-allergy nasal spray
Bentrio
    ** In this context has suspended the launch preparations for
Bentrio in the U.S. on its own as well as major market
initiatives in Europe
    ** Expects to report first half 2022 revenues related to
Bentrio of $1.3 million
    ** CYTO down 78.1% YTD

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))